Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

J. T. Hutton; W. C. Koller; J. E. Ahlskog; R. Pahwa; H. I. Hurtig; M. B. Stern; B. C. Hiner; A. Lieberman; R. F. Pfeiffer; R. L. Rodnitzky; C. H. Waters; M. D. Muenter; C. H. Adler; J. L. Morris

doi:10.1212/WNL.46.4.1062

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

J. T. Hutton, W. C. Koller, J. E. Ahlskog, R. Pahwa, H. I. Hurtig, M. B. Stern, B. C. Hiner, A. Lieberman, R. F. Pfeiffer, R. L. Rodnitzky, C. H. Waters, M. D. Muenter, C. H. Adler, J. L. Morris

Research output: Contribution to journal › Article › peer-review

94 Scopus citations

Abstract

Cabergoline is a dopaminergic agonist relatively specific for the D₂ receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.

Original language	English (US)
Pages (from-to)	1062-1065
Number of pages	4
Journal	Neurology
Volume	46
Issue number	4
DOIs	https://doi.org/10.1212/WNL.46.4.1062
State	Published - Apr 1996
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.46.4.1062

Cite this

Hutton, J. T., Koller, W. C., Ahlskog, J. E., Pahwa, R., Hurtig, H. I., Stern, M. B., Hiner, B. C., Lieberman, A., Pfeiffer, R. F., Rodnitzky, R. L., Waters, C. H., Muenter, M. D., Adler, C. H., & Morris, J. L. (1996). Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology, 46(4), 1062-1065. https://doi.org/10.1212/WNL.46.4.1062

Hutton, JT, Koller, WC, Ahlskog, JE, Pahwa, R, Hurtig, HI, Stern, MB, Hiner, BC, Lieberman, A, Pfeiffer, RF, Rodnitzky, RL, Waters, CH, Muenter, MD, Adler, CH & Morris, JL 1996, 'Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease', Neurology, vol. 46, no. 4, pp. 1062-1065. https://doi.org/10.1212/WNL.46.4.1062

@article{4b761250fef34da2a53c4bcca740ff52,

title = "Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease",

abstract = "Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.",

author = "Hutton, {J. T.} and Koller, {W. C.} and Ahlskog, {J. E.} and R. Pahwa and Hurtig, {H. I.} and Stern, {M. B.} and Hiner, {B. C.} and A. Lieberman and Pfeiffer, {R. F.} and Rodnitzky, {R. L.} and Waters, {C. H.} and Muenter, {M. D.} and Adler, {C. H.} and Morris, {J. L.}",

year = "1996",

month = apr,

doi = "10.1212/WNL.46.4.1062",

language = "English (US)",

volume = "46",

pages = "1062--1065",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

AU - Hutton, J. T.

AU - Koller, W. C.

AU - Ahlskog, J. E.

AU - Pahwa, R.

AU - Hurtig, H. I.

AU - Stern, M. B.

AU - Hiner, B. C.

AU - Lieberman, A.

AU - Pfeiffer, R. F.

AU - Rodnitzky, R. L.

AU - Waters, C. H.

AU - Muenter, M. D.

AU - Adler, C. H.

AU - Morris, J. L.

PY - 1996/4

Y1 - 1996/4

N2 - Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.

AB - Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.

UR - http://www.scopus.com/inward/record.url?scp=9244228479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244228479&partnerID=8YFLogxK

U2 - 10.1212/WNL.46.4.1062

DO - 10.1212/WNL.46.4.1062

M3 - Article

C2 - 8780092

AN - SCOPUS:9244228479

SN - 0028-3878

VL - 46

SP - 1062

EP - 1065

JO - Neurology

JF - Neurology

IS - 4

ER -

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this